Total Payments
$2,939
2022 Payments
$436.89
Companies
19
Transactions
106
Medicare Patients
14,311
Medicare Billing
$2.1M
Payment Breakdown by Category
Food & Beverage$2,918 (99.3%)
Education$20.97 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,918 | 103 | 99.3% |
| Education | $20.97 | 3 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $735.10 | 28 | $0 (2022) |
| Braemar Manufacturing, LLC | $527.34 | 2 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $295.30 | 11 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $236.34 | 11 | $0 (2019) |
| PFIZER INC. | $171.72 | 14 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $161.58 | 4 | $0 (2020) |
| Amarin Pharma Inc. | $129.31 | 2 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $121.84 | 9 | $0 (2022) |
| Medtronic Vascular, Inc. | $103.93 | 1 | $0 (2018) |
| Aralez Pharmaceuticals US Inc. | $96.88 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $436.89 | 15 | E.R. Squibb & Sons, L.L.C. ($270.74) |
| 2020 | $256.67 | 10 | Amgen Inc. ($147.05) |
| 2019 | $369.18 | 20 | Amarin Pharma Inc. ($112.23) |
| 2018 | $749.01 | 20 | Braemar Manufacturing, LLC ($183.93) |
| 2017 | $1,127 | 41 | Braemar Manufacturing, LLC ($343.41) |
All Payment Transactions
106 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2022 | Philips Electronics North America Corporation | (5044) MCOT (Device) | Food and Beverage | Cash or cash equivalent | $19.97 | General |
| Category: Medical Device | ||||||
| 12/08/2022 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/16/2022 | Merck Sharp & Dohme LLC | VERQUVO (Drug) | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/26/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $21.10 | General |
| Category: Cardiovascular | ||||||
| 10/12/2022 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $117.40 | General |
| Category: Cardiovascular | ||||||
| 10/12/2022 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $15.10 | General |
| Category: Cardiovascular | ||||||
| 09/15/2022 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $8.46 | General |
| Category: Cardiovascular | ||||||
| 08/17/2022 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 07/20/2022 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $11.32 | General |
| Category: Cardiovascular | ||||||
| 06/28/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $2.70 | General |
| Category: Cardiovascular | ||||||
| 05/05/2022 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $21.88 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/28/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $13.20 | General |
| Category: Cardiovascular | ||||||
| 04/19/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $78.37 | General |
| 03/30/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $3.09 | General |
| Category: Cardiovascular | ||||||
| 03/10/2022 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $81.00 | General |
| Category: Cardiology | ||||||
| 03/03/2020 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: CARDIOVASCULAR | ||||||
| 02/25/2020 | PFIZER INC. | ELIQUIS (Drug), VYNDAQEL | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 02/11/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $12.91 | General |
| Category: DIABETES | ||||||
| 02/04/2020 | Astellas Pharma US Inc | LEXISCAN (Drug) | Food and Beverage | In-kind items and services | $21.40 | General |
| Category: HOSPITAL AND TRANSPLANT | ||||||
| 01/28/2020 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: Cardiovascular | ||||||
| 01/23/2020 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/16/2020 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $108.34 | General |
| Category: Cardiology | ||||||
| 01/15/2020 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: Cardiology | ||||||
| 01/14/2020 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/08/2020 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $20.96 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 40 | 3,184 | 6,720 | $989,262 | $373,634 |
| 2021 | 46 | 5,387 | 15,497 | $2.3M | $891,806 |
| 2020 | 48 | 5,740 | 15,860 | $2.2M | $833,029 |
Total Patients
14,311
Total Services
38,077
Medicare Billing
$2.1M
Procedure Codes
148
All Medicare Procedures & Services
148 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 494 | 940 | $203,040 | $82,064 | 40.4% |
| 78492 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress | Office | 2022 | 43 | 43 | $127,022 | $51,154 | 40.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 220 | 223 | $92,322 | $31,851 | 34.5% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2022 | 188 | 190 | $76,760 | $27,314 | 35.6% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2022 | 43 | 86 | $68,628 | $27,301 | 39.8% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 71 | 71 | $68,302 | $23,476 | 34.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 137 | 138 | $57,270 | $21,490 | 37.5% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2022 | 73 | 292 | $32,996 | $14,311 | 43.4% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2022 | 72 | 144 | $33,984 | $12,950 | 38.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 73 | 83 | $24,446 | $10,441 | 42.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 566 | 1,073 | $36,482 | $10,381 | 28.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 73 | 116 | $24,708 | $9,397 | 38.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 134 | 134 | $19,966 | $6,868 | 34.4% |
| 93280 | Programming of dual lead pacemaker system | Office | 2022 | 66 | 102 | $11,934 | $6,008 | 50.3% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2022 | 115 | 115 | $16,330 | $5,961 | 36.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 57 | 76 | $11,324 | $4,305 | 38.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 72 | 76 | $11,172 | $4,170 | 37.3% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2022 | 67 | 188 | $11,844 | $4,046 | 34.2% |
| 93356 | Heart muscle strain imaging | Office | 2022 | 69 | 70 | $5,600 | $2,050 | 36.6% |
| 93308 | Ultrasound of heart, follow-up | Office | 2022 | 28 | 28 | $5,824 | $1,977 | 34.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 15 | 15 | $4,200 | $1,614 | 38.4% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2022 | 34 | 91 | $4,732 | $1,542 | 32.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 14 | 17 | $3,669 | $1,325 | 36.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $4,008 | $1,303 | 32.5% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2022 | 11 | 62 | $3,348 | $1,142 | 34.1% |
About Dr. Michael Dillon, MD
Dr. Michael Dillon, MD is a Cardiovascular Disease healthcare provider based in Gainesville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1285600148.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Dillon, MD has received a total of $2,939 in payments from pharmaceutical and medical device companies, with $436.89 received in 2022. These payments were reported across 106 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($2,918).
As a Medicare-enrolled provider, Dillon has provided services to 14,311 Medicare beneficiaries, totaling 38,077 services with total Medicare billing of $2.1M. Data is available for 3 years (2020–2022), covering 148 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Gainesville, FL
- Active Since 02/28/2006
- Last Updated 10/18/2016
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1285600148
Products in Payments
- Cardiac Monitoring Suite (Device) $527.34
- Repatha (Biological) $502.30
- XARELTO (Drug) $236.34
- ELIQUIS (Drug) $224.15
- Corlanor (Drug) $218.80
- JARDIANCE (Drug) $161.58
- CAMZYOS (Drug) $152.28
- Vascepa (Drug) $129.31
- ENTRESTO (Drug) $121.84
- Resolute (Device) $103.93
- YOSPRALA (Drug) $96.88
- PRALUENT (Drug) $92.96
- NORTHERA (Drug) $66.85
- BRILINTA (Drug) $60.86
- LEXISCAN (Drug) $44.75
- (5044) MCOT (Device) $19.97
- LifeVest (Device) $14.55
- VERQUVO (Drug) $13.69
- Lexiscan (Drug) $12.59
- LOKELMA (Drug) $12.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Gainesville
Dr. Juan Aranda, Md, MD
Cardiovascular Disease — Payments: $357,500
Cardiovascular Disease $357,500
Mudassar Ahmed, Mbbs, MBBS
Cardiovascular Disease — Payments: $337,874
Cardiovascular Disease $337,874
Dr. Matheen Khuddus, M.d, M.D
Cardiovascular Disease — Payments: $223,657
Cardiovascular Disease $223,657
Dr. Ann Tong, Md, MD
Cardiovascular Disease — Payments: $198,583
Cardiovascular Disease $198,583
Dr. Carl Pepine, Md, MD
Cardiovascular Disease — Payments: $195,635
Cardiovascular Disease $195,635
Dr. Michael Koren, M.d, M.D
Cardiovascular Disease — Payments: $193,105
Cardiovascular Disease $193,105